Skip to content

Bernadette Connaughton, Director at Halozyme Therapeutics, sold HALO on Jul 1, 2026

Data as of Oct 16

▼ SELL$76.4K1,000 shares at $76.39Bernadette Connaughton DirectorHALO Halozyme Therapeutics, Inc.
Watch HALO
Traded
Jul 1, 2026
Disclosed
Jul 2, 2026
Filed
1 day after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Bernadette Connaughton, Director at Halozyme Therapeutics, sold HALO on Jul 1, 2026TRADEDDISCLOSED
HALOSimilar stocks (XLV — its sector index fund), rebased to HALO's price on the disclosure day
HALO since disclosure
+53.4%
after the sale
Similar stocks (XLV) since disclosure
+7.9%
XLV — its sector index fund

Change in closing price from Jul 2, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLBernadette Connaughton DirectorHALO Halozyme Therapeutics, Inc.$48.3Kdisclosed Jul 2 · filed 1 day after the trade

See every trade on HALO →